NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics Inc (NASDAQ:FPRX) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.08. The biotechnology company earned $32.49 million during the quarter, compared to analyst estimates of $37.50 million. Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. View Five Prime Therapeutics' Earnings History.

8 brokerages have issued twelve-month price targets for Five Prime Therapeutics' shares. Their predictions range from $17.00 to $60.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $34.7143 in the next year. This suggests a possible upside of 104.6% from the stock's current price. View Analyst Ratings for Five Prime Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Five Prime Therapeutics include Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), Arena Pharmaceuticals (ARNA), TESARO (TSRO), Global Blood Therapeutics (GBT), ACADIA Pharmaceuticals (ACAD), Zogenix (ZGNX), Myokardia (MYOK), Puma Biotechnology (PBYI), Phibro Animal Health (PAHC), Insmed (INSM), Prestige Brands (PBH), PTC Therapeutics (PTCT) and Cambrex (CBM).

Media stories about FPRX stock have trended very positive recently, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.51 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 48.24 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Five Prime Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fox Run Management L.L.C. (0.07%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

FPRX stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $16.97.

Five Prime Therapeutics has a market capitalization of $597.50 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.